Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: Jorgen Jensen who wrote (464)	3/2/1999 4:21:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

from SIBI 10-K405...... Cognetix, Inc. In July 1996, SIBIA entered into an agreement with Cognetix, Inc. ("Cognetix") to conduct research on conopeptides (peptides derived from different Conus species of marine snails) with the objective of identifying and characterizing highly selective compounds for different receptors and ion channels found on nerve cells. Such compounds could have potential as therapeutics for nervous system disorders. In addition, the agreement provides SIBIA with a nonexclusive license to use certain materials for research purposes and with an option for an exclusive, worldwide license to intellectual property and specific molecules resulting from the collaborative work. Under the collaborative agreement, SIBIA will apply its proprietary functional drug screening assays to specific conopeptides and Conus venoms supplied by Cognetix.